4.40Open4.40Pre Close0 Volume3 Open Interest2.50Strike Price0.00Turnover631.04%IV-27.67%PremiumAug 16, 2024Expiry Date7.04Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9494Delta0.0067Gamma1.22Leverage Ratio-0.0338Theta0.0008Rho1.16Eff Leverage0.0026Vega
Alignment Healthcare Stock Discussion
In reaction to earnings/guidance:
• $AutoZone(AZO.US)$ +2.7%, $Jacobs Engineering(J.US)$ +0.9% (reaffirms Q4 EPS and adjusted EBITDA guidance)
Other news:
• $Purple Innovation(PRPL.US)$ +32.6% (confirms it received an unsolicited, non-binding proposal from Coliseum Capital Management to acquire all of the outstanding capital stock of Purple for $4.35 per share)
• $KnowBe4(KNBE.US)$ +24.9% (received a non-binding proposal f...
In reaction to earnings/guidance:
• $Bowlero(BOWL.US)$ +3.4%
Other news:
• $Intellia Therapeutics(NTLA.US)$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $Gogo Inc(GOGO.US)$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADC Therapeutics(ADCT.US)$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
• $Oscar Health(OSCR.US)$ BofA analyst Kevin Fischbeck downgraded Oscar Health to Neutral from Buy with a price target of $6, down from $12. The analyst sees greater medical loss ratio uncertainty into 2023. The industry is going to have to manage through the expiration of the expanded Affordable Care Act subsidies, Medicaid redeterminations and the result shift within the risk pool making it more difficult to price, Fischb...
No comment yet